176 Recruiting Trials

Clinical Trials
for Breast Cancer in Massachusetts

176 clinical trials for Breast Cancer are currently recruiting participants at study sites in Massachusetts. Study-related care is provided at no cost.

176
Recruiting trials
102
Study sites
32
Cities
90
Industry-sponsored
56
Phase 2
31
Phase 3

Breast Cancer clinical trials in Massachusetts: what to expect

Breast cancer trials are sorted first by subtype, because the treatments differ: hormone-receptor-positive, HER2-positive (including the newer HER2-low group) and triple-negative disease each have their own studies. Most recruiting trials test a new drug or combination, including targeted pills, antibody-drug conjugates and immunotherapy, either for metastatic cancer or before and after surgery for early-stage disease. Others study less surgery or radiation, ways to reduce recurrence, and screening for people at higher risk.

In Massachusetts, recruiting breast cancer studies are concentrated in Boston, Burlington, Foxborough and Springfield, with sites in 28 other cities. 90 of the 176 are run by a drug or device company, which usually means a larger study with travel reimbursement; the rest are academic or hospital-led.

Who breast cancer trials usually look for

Listings name the subtype, the stage (early or metastatic) and how many treatments you may already have had. Early-stage trials often enroll between diagnosis and surgery, or in the months after surgery; metastatic trials usually enroll when a treatment has stopped working. Some specify menopausal status or a particular mutation (BRCA, PIK3CA, ESR1), which the site can test for. Nearly all require that you are well enough for daily activity and that recent blood work is adequate.

Your receptor status is on your pathology report; the site will confirm it from that report, so you do not need to know it by heart to ask.

What taking part involves

Screening reviews your pathology and scans and adds blood work, sometimes a biopsy. Treatment then runs in cycles, with infusions every two to three weeks or daily pills, and scans every two to three months to check the response. Early-stage trials follow you for years after treatment ends, usually with a visit or call every few months. Study drugs and study-specific tests are free; care you would receive anyway is billed to insurance as usual. Placebo, when used, is added to standard treatment.

Questions worth asking the study team

How the study treatment compares with what your oncologist would otherwise recommend; whether the trial is randomized and what the other arm receives; what happens if the cancer grows or returns; and how visits fit around work and family. Many trials now allow some visits at a local clinic.

Showing 20 of 176 recruiting Breast Cancer trials in Massachusetts

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
PHASE3 Anchorage, Alaska +4 sites NCT07062965
This trial is looking for people with HR-positive, HER2-negative advanced breast cancer that has worsened after previous treatment. Participants will receive the study medicine PF-07248144 along with their normal treatment options to see how well they work together.
Recruiting
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
PHASE3 Jonesboro, Arkansas +4 sites NCT06757634
This trial is looking for adults with advanced breast cancer that is HR-positive and HER2-negative. Participants will receive treatment involving gedatolisib along with other medications.
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
PHASE3 Greenbrae, California +4 sites NCT05646862
This trial is looking for people with advanced breast cancer that has specific mutations and has not improved after certain treatments. Participants will compare two treatment combinations to see which is more effective and safe.
Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
PHASE3 Daphne, Alabama +4 sites NCT06103864
This trial is looking for patients with a specific type of breast cancer that is not treatable by surgery. Participants will receive a treatment called Dato-DXd, with or without another drug, or a standard chemotherapy treatment.
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
PHASE3 Hot Springs, Arkansas +4 sites NCT07085767
This trial is looking for adults with advanced breast cancer that hasn’t been treated before. Participants will receive palazestrant with ribociclib or letrozole with ribociclib to see which treatment works better.
Recruiting
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
PHASE3 Daphne, Alabama +4 sites NCT06492616
This trial is looking for women and men with early breast cancer that has a high risk of coming back. Participants will compare the effects of elacestrant with standard treatment after being on another therapy for a while.
Recruiting
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
PHASE3 Birmingham, Alabama +4 sites NCT05879926
This trial is looking for premenopausal women with early-stage breast cancer that is hormone receptor-positive. Participants will receive hormone therapy and may also get chemotherapy to see if it helps them live longer without cancer returning.
Recruiting
E-Mindfulness Approaches for Living After Breast Cancer
PHASE3 Phoenix, Arizona +4 sites NCT06748222
This trial is looking for younger women who have survived breast cancer and are experiencing depression. Participants will try two different mindfulness programs, one led by an instructor via Zoom and the other through a mobile app.
Recruiting
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
PHASE3 Boston, Massachusetts +4 sites NCT05950945
This trial is looking for people with certain types of breast cancer to see how a treatment called trastuzumab deruxtecan works. Participants need to provide tissue samples and meet specific health criteria.
Recruiting
TRUDI: TDXD+Durva in HER2+/Low IBC
PHASE2 Boston, Massachusetts +2 sites NCT05795101
This trial is looking for people with stage III inflammatory breast cancer that is HER2-positive. Participants will receive a combination of two investigational drugs and will need to undergo some research biopsies of their tumors.
Recruiting
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
PHASE1 Huntsville, Alabama +4 sites NCT07100106
This trial is looking for people with advanced breast cancer that is hormone receptor positive and HER2 negative. Participants will receive GDC-4198 by itself or with another drug, Giredestrant, to see how well it works and compare it to another treatment option.
Recruiting
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
PHASE2 Birmingham, Alabama +4 sites NCT06533826
This trial is looking for women with advanced breast cancer that is HER2-negative. Participants will take part in a treatment involving two investigational drugs to see how effective they are.
Recruiting
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
PHASE2 Boston, Massachusetts NCT07222215
This trial is looking for adults with advanced estrogen receptor-positive breast cancer that has not responded to certain previous treatments. Participants will receive a combination of two medications: capecitabine and elacestrant.
Recruiting
ATEMPT 2.0: Adjuvant T-DM1 vs TH
PHASE2 San Francisco, California +4 sites NCT04893109
This trial is looking for patients with early-stage breast cancer that tests positive for HER2. Participants will receive one of two treatment options after surgery to see how well they work.
Recruiting
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
PHASE2 Boston, Massachusetts +2 sites NCT06176261
This trial is looking for adults with breast cancer that has spread to the brain. Participants will take a study drug called datopotamab deruxtecan and undergo imaging tests to confirm their condition.
Recruiting
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
PHASE2 Boston, Massachusetts NCT06439693
This trial is looking for women with a specific type of breast cancer called HER2-positive and who have not received treatment before. Participants will take a series of medications to see how well they work and if they are safe.
Recruiting
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
PHASE1 Boston, Massachusetts NCT07198724
This trial is looking for adults with a specific type of metastatic breast cancer that has not responded to previous treatments. If eligible, participants will receive two study drugs, elacestrant and trastuzumab deruxtecan, to evaluate their safety and effectiveness.
Recruiting
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
PHASE2 Boston, Massachusetts +4 sites NCT03990896
This trial is looking for women with advanced breast cancer that has certain genetic mutations. Participants will take a medication called Talazoparib to see how well it works in treating their condition.
Recruiting
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
PHASE2 Boston, Massachusetts +4 sites NCT04434040
This trial is looking for people with residual triple negative breast cancer after chemotherapy who have detected tumor DNA in their blood. Participants will take a combination of two drugs to see if it helps prevent cancer from coming back.
Recruiting
VS-6766+Abema+Fulv in Met HR+/HER- BC
PHASE1 Boston, Massachusetts +2 sites NCT05608252
Recruiting

Where the Breast Cancer studies are in Massachusetts

  • Dana-Farber Cancer Institute, Boston56 trials
  • Massachusetts General Hospital, Boston49 trials
  • Dana Farber Cancer Institute, Boston38 trials
  • Beth Israel Deaconess Medical Center, Boston17 trials
  • Brigham and Women's Hospital, Boston12 trials
  • Boston Medical Center, Boston9 trials

Counts are recruiting studies listing at least one site in Massachusetts, from ClinicalTrials.gov, refreshed every two days.

Breast Cancer clinical trials in Massachusetts: common questions

How many Breast Cancer clinical trials are recruiting in Massachusetts?
TrialFinder currently lists 176 recruiting Breast Cancer clinical trials with study sites in Massachusetts. Results are updated regularly from ClinicalTrials.gov, the official U.S. registry of clinical studies.
Where are Breast Cancer clinical trials located in Massachusetts?
Study sites for the Breast Cancer trials listed on this page include Boston. Each trial page lists every participating site with contact details, so you can find the location closest to you.
Do I need insurance to join a Breast Cancer clinical trial in Massachusetts?
No. Study-related care is covered by the trial sponsor at no cost to participants, including the study treatment, required lab tests and study visits. Many Breast Cancer trials in Massachusetts also compensate participants for time and travel. Health insurance is not required to search or enroll.
How do I qualify for a Breast Cancer clinical trial in Massachusetts?
Each study sets its own criteria based on age, Breast Cancer diagnosis details, prior treatments, current medications and general health. The fastest way to find out is to contact a research site directly — most will pre-screen you by phone in 10 to 15 minutes at no charge. You can also create a free TrialFinder profile to be matched automatically.
Do I need to know my receptor status to join a breast cancer trial?
It helps, because trials are organized by subtype, but the study site reads it from your pathology report. If a trial needs a test you have not had, such as HER2-low or a BRCA result, the site arranges it.
Are there trials for early-stage breast cancer?
Yes. Early-stage trials enroll before surgery, after surgery, or during the years of hormone therapy that follow, and test ways to lower the chance the cancer returns. The listing says which window it enrolls in.
Will a trial replace the treatment my oncologist planned?
Sometimes it is the plan, with a new drug added or compared; sometimes it is an alternative to discuss. Bring the trial page to your oncologist, who can refer you to the site or advise on timing.
Are Clinical Trials Safe? What Patients Should Know
How clinical trial safety works — phases, IRB oversight, informed consent, and your right to withdraw — plus the real risks and questions to ask.
How to Know If You Qualify for a Clinical Trial
Every trial has eligibility criteria based on diagnosis, age, and medical history. Here's how to tell if you qualify — and what to do if you're not sure.
Clinical Trials Without Insurance: What You Need to Know
Clinical trials cover the cost of study-related care, making them one of the few ways to access treatment without health insurance. Here's what's covered.
All guides →

Check Your Eligibility

Create a free profile and our AI will match you to Breast Cancer trials near you in Massachusetts.

Get Matched — Free
No insurance required

Breast cancer trials test new chemotherapy regimens, immunotherapy combinations, targeted therapies, and early-detection methods across all stages of breast cancer.

All Breast Cancer trials →